key: cord-0037288-f6sz8qrv authors: Ginocchio, Christine C. title: Respiratory Infections date: 2015-05-19 journal: Molecular Pathology in Clinical Practice DOI: 10.1007/978-3-319-19674-9_52 sha: bdd3a555b2d321c9b2993278c863d229f5141639 doc_id: 37288 cord_uid: f6sz8qrv The majority of respiratory tract infections (RTIs) are community acquired and are the single most common cause of physician office visits and among the most common causes of hospitalizations. The morbidity and mortality associated with RTIs are significant and the financial and social burden high due to lost time at work and school. The scope of clinical symptoms can significantly overlap among the respiratory pathogens, and the severity of disease can vary depending on patient age, underlying disease, and immune status, thereby leading to inaccurate presumptions about disease etiology. The rapid and accurate diagnosis of the causative agent of RTIs improves patient care, reduces morbidity and mortality, promotes effective hospital bed utilization and antibiotic stewardship, and reduces length of stay. This chapter focuses on the clinical utility, advantages, and disadvantages of viral and bacterial tests cleared by the Food and Drug Administration (FDA), and new promising technologies for the detection of bacterial agents of pneumonia currently in development or in US FDA clinical trials are briefly reviewed. The majority of respiratory tract infections (RTIs) are community-acquired and are the single most common cause of physician offi ce visits and among the most common causes of hospitalizations [ 10 , 68 , 146 , 182 , 194 ] . The morbidity and mortality associated with RTIs are signifi cant and the fi nancial and social burden high due to lost time at work and school. Viral infections cause between 65 -80 % of respiratory tract diseases with mixed viral infections present in 5-20 % of viral RTIs in adults and as high as 62 % in studies of children ≥ 6 years of age [ 66 , 80 , 132 , 172 , 182 , 194 ] . In Europe and in the USA the incidence of pneumonia due to a bacterial pathogen is 1-10 cases per 10,000 inhabitants, depending on various factors such as age. The differentiation of viral from bacterial RTIs can be assisted considering the rate of onset of illness, patient age, symptoms, radiographic changes, biomarkers, response to treatment, and the presence of documented viral epidemics in the community. However, the scope of clinical symptoms can signifi cantly overlap among the respiratory pathogens, and the severity of disease can vary depending on patient age, underlying disease, and immune status, thereby leading to inaccurate presumptions about disease etiology. Numerous studies have demonstrated that a rapid and accurate diagnosis of the causative agent of RTIs improves patient care, reduces morbidity and mortality, promotes effective hospital bed utilization and antibiotic stewardship, and reduces length of stay [ 9 , 20 , 22 , 82 , 92 , 106 , 115 , 120 , 121 , 142 , 160 , 170 , 191 , 227 , 229 , 234 ] . Pathogen etiology may need to be considered in the clinical management of certain patients, such as immunocompromised patients or young infants, if there is a potential for the development of more severe disease [ 13 , 65 , 68 , 80 , 81 , 86 , 194 ] . In health care settings, the identifi cation of a viral RTI prompts the initiation of appropriate infection control measures, thereby reducing morbidity and mortality associated with nosocomial transmission [ 19 , 39 , 40 , 62 , 126 , 155 , 217 , 219 ] . Over the last several years great advances have been made in obtaining USA Food and Drug Administration (FDA) clearance for a variety of nucleic acid amplifi cation tests (NAATS) that detect single or multiple viral respiratory pathogens and three bacterial pathogens ( Mycoplasma pneumoniae , Chlamydophila pneumoniae , Bordetella pertussis ). This chapter focuses on the clinical utility, advantages, and disadvantages of these tests. Unfortunately, no FDA-cleared assays are available for the detection of the majority of bacterial and fungal pathogens associated with communityacquired pneumonia (CAP), hospital-associated pneumonia (HAP), and ventilator-associated pneumonia (VAP). New promising technologies for the detection of bacterial agents of pneumonia currently in development or US FDA clinical trials are briefl y reviewed. Although sensitive, accurate fungal diagnostics is an area of importance, the development of new diagnostic assays has been signifi cantly delayed. Hence, for the detection of the vast majority of the nonviral pathogens, laboratory developed tests (LDTs) are the mainstay of molecular testing and will not be discussed. The importance of new rapid diagnostics for CAP, VAP, and HAP has been highlighted by a workshop conducted in November 2009 by the Infectious Diseases Society of America (IDSA) in collaboration with the FDA, the proceedings of which have been published in a special supplement of Clinical Infectious Diseases [ 102 ] . The IDSA, in an executive summary of the workshop, states that there is "a need to develop and implement modern molecular technologies to advance microbiological diagnostic testing." The common viruses that cause both lower RTIs (LRTIs) and upper RTIs (URTIs) are listed in Table 52 .1 . Overall, viruses are the most common cause of URTIs and the second most common etiologic cause of CAP (behind Streptococcus pneumoniae ), ranging from 13 -50 % of diagnosed cases [ 10 , 146 , 132 , 172 , 182 , 194 ] . CAP in children is predominately of viral etiology, with the majority of the infections caused by respiratory syncytial virus (RSV), human rhinovirus (HRV), human metapneumovirus (HMPV), and parainfl uenza viruses 1, 2, 3, 4 (PIV) [ 99 , 194 ] . Infl uenza A (FluA) and infl uenza B (FluB), adenovirus (ADV), and the coronaviruses (CoVs) are additional causes of CAP in children. RTIs in non-immune compromised hospitalized children (especially < 5 years of age), are mainly due to infection with one or multiple viruses without a secondary bacterial infection. Viral CAP decreases in frequency in healthy young and middle-aged adults to about one-third of the cases, with infl uenza, HRV, and CoV being the most common agents. Viral CAP rates substantially increase among the elderly, often complicated by secondary bacterial infection. The most common viral causes of CAP in the elderly are infl uenza and RSV; however, HMPV, PIVs, CoVs, and HRV cause both URTIs and LRTIs [ 66 , 194 ] . Since 2008 several clusters of respiratory illness associated with human enterovirus 68 (HEV68) were reported in Asia, Europe, and the USA (MMWR [ 29 ] ). HEV68, a unique enterovirus with similar biologic features to HRV, was associated with RTIs ranging from relatively mild illness to severe illness requiring intensive care and mechanical ventilation. Severe disease was particularly pronounced in children (MMWR [ 29 ] ). Although human bocavirus (HBoV) has been implicated as a cause of RTI, in the majority of cases HBoV is detected in conjunction with other viral pathogens and the clinical signifi cance of HBoV is still debated [ 105 , 200 ] . HBoV is more commonly found in children; however, HBoV can affect persons of all ages. Underlying disease, such as cancer, is associated with severe infections requiring hospitalization. Generally the CoVs (NL-63, OC43, HKU-1, 229E) cause mild, self-limiting URTIs such as the common cold. However, in the last decade, two CoVs-Severe Acute Respiratory Syndrome (SARS-CoV) and the Middle East Respiratory Syndrome (MERS-CoV) have emerged with a potential pandemic threat due to person-to-person communicability [ 33 ] . Both viruses can cause severe lower respiratory tract disease with extrapulmonary involvement and are associated with high case-fatality rates. Although SARS-CoV is currently not circulating, since 2012 MERS-CoV continues to cause outbreaks in the Middle East with secondary spread to Europe, Africa, Asia, and North America. The prevalence of each viral pathogen can vary depending on environmental conditions (climate, season, geographic location). For example, in the New York City area, adenovirus (ADV) tends to circulate with the same prevalence year round ( Fig. 52.1a ) , while RSV can be detected sporadically year round with the peak season in October through February ( Fig. 52 .1b ) (unpublished data provided by author). The "classic" infl uenza season begins generally in late October and wanes during April. HMPV prevalence tends to rise as RSV season wanes in February and peaks in the spring, PIV-1 and PIV-4 are most prevalent in the summer through fall, while PIV-3 prevails in the spring and PIV-2 in the fall. Virus prevalence also can be patient population driven (e.g., pediatric, adult, geriatric, outpatient, or inpatient). For example, RSV and HMPV are primarily found in children < 5 years of age, but can cause severe disease in all age groups [ 64 , 65 , 94 , 97 ] . In the immunosuppressed population, other less common respiratory viral pathogens, such as herpes simplex virus (HSV) and cytomegalovirus (CMV), must be considered as a potential cause of RTIs. The major bacterial pathogens responsible for CAP ( (3-5 %) , Haemophilus infl uenzae (3-10 %), variable gram-negative rods (3-10 %), and rarely Neisseria meningitidis (<1 %) depending on the patient and underlying diseases such as chronic obstructive pulmonary disease (COPD) or asthma [ 10 , 146 ] . Moraxella cattharalis is generally associated with otitis media in children and exacerbation of asthma and COPD in adults. The classic atypical pathogens that cause CAP include C. pneumoniae , M. pneumoniae , and Legionella pneumophila , which also can be nosocomially acquired in institutional settings [ 10 , 17 , 46 , 67 , 222 ] . The majority of RTIs (up to 70 %) caused by C. pneumoniae are asymptomatic or have minimal symptoms. C. pneumoniae accounts for 6-20 % of CAP and 5 % of cases of sinusitis, pharyngitis, tracheitis, bronchiolitis, bronchitis, and exacerbations of chronic bronchitis and asthma in both immunocompetent and immunosuppressed persons [ 17 , 42 ] . C. pneumoniae can be present with other bacterial pathogens in up to 30 % of adult cases of CAP. C. pneumoniae infection can present with varied clinical courses from mild, selflimiting disease to severe forms of pneumonia, particularly in patients with cardiopulmonary disease and in the elderly [ 17 ] . All age groups are affected; however, C. pneumoniae infections are rarely found in young children < 5 years of age. However, by age 20, 50 % of persons have detectable antibody levels, with the elderly demonstrating a seropositivity rate between 70 -80 % [ 221 ] . M. pneumoniae is estimated to cause 6-20 % of the cases of CAP [ 222 ] . Although most infections are asymptomatic, mild, and often self-limiting, approximately 1-5 % of infections may require hospitalization and can lead to serious extrapulmonary complications. LRTIs are more common in school age children and adolescents, with the prevalence in pediatric LRTI ranging from 10-40 %. M. pneumoniae infection can cause outbreaks in the community and institutions such as schools, prisons, and hospitals. Legionella spp. causes two distinct clinical entities. Pontiac Fever is a self-limiting fl u-like illness and Legionaire's disease is a severe multisystem disease involving pneumonia. Cases can be sporadic or part of outbreaks due to environmental exposure [ 51 , 67 ] . L. pneumophila is responsible for 2-8 % of CAP and is responsible for 2-15 % of all CAP that require hospitalization. L. pneumophila (serogroup 1) is responsible for 90 % of the diagnosed disease, most probably because the major diagnostic tests are specifi c for this serogroup. Risk factors for contracting Legionellosis include smoking, immunosuppression, age ≥ 65, chronic lung disease such as emphysema, diabetes, kidney disease, cancer, or contact with environmental systems such as air conditioning cooling towers, evaporative condensers, whirlpools, and hot spring baths. Coxiella burnetii , an obligate gram-negative intracellular bacterium has primary reservoirs in cattle, sheep, and goats. Transmission to humans occurs primarily through inhalation of aerosols from contaminated soil or animal waste. Most C. burnetti infections are manifested as Q Fever, a self-limited, infl uenza-like febrile illness (88-100 %) of abrupt onset, manifested by chills, headache, myalgia, fatigue, and sweats; ( [ 150 ] , CDC MMWR [ 30 ] ). However, pneumonia is predominant in North America and usually mild in nature. Patients have dyspnea, pleuritic chest pain, and a dry, nonproductive cough. Rarely, C. burnetti infection occasionally can progress to acute respiratory distress syndrome (ARDS) ( [ 150 ] , CDC MMWR [ 30 ] ). B. pertussis is the cause of whooping cough [ 43 , 119 ] . Pertussis-like illness can be attributed to Bordetella parapertussis , Bordetella holmseii , and rarely Bordetella bronchioseptica infections. Overall, Bordetella infections have increased dramatically over the last 10 years due to waning immunity, incomplete antibody response to vaccination with acellular vaccines, or lack of vaccination. Recent epidemics have occurred between 2010 and 2014. In 2010, more than 27,000 cases were reported, of which over 9,000 occurred in California. Nationwide by 2013 more than 28,000 cases were reported to the CDC ( http://www.cdc.gov/pertussis/ surv-reporting.html ). The highest incidence was noted in infants < 1 year of age, but a signifi cant amount of disease occurred among children aged 7-10 years. One large outbreak of pertussis-like illness in Ohio from 2010 to 2011 was attributed to both B. pertussis (68 % of the cases) and B. holmseii (29 % of the cases) [ 190 ] . Outbreaks of pertussis continue, highlighting the need for primary vaccination and the administration of "Tdap" booster immunizations. HAP and VAP are more often associated with drugresistant, multidrug-resistant, or pan-resistant bacteria, such as MRSA, extended-spectrum beta-lactamase (ESBL)producing Enterobacteriacae , or carbapenemase-producing Enterobacteriacae , Pseudomonas spp., Acinetobacter spp., and Stenotrophomonas maltophilia [ 4 ] . For patients in the intensive care unit (ICU) or immunocompromised patients, other pathogens such as Nocardia spp, Corynebacterium spp., Pneumocystis jiroveci , Fusarium spp., Aspergillus spp, Cryptococcus spp., and the zygomycetes need to be considered in the differential diagnosis. Conventional virus detection methods include rapid antigen detection tests (RADTs), direct fl uorescent antibody tests (DFAs), rapid cell culture, and traditional tube culture [ 125 ] . Although these methods are acceptable diagnostic tools in certain clinical settings, they are often inferior in the breadth of pathogens identifi ed, assay sensitivity, and result turnaround time, when compared to NAATs [ 18 , 28 , 39 , 73 , 74 , 79 , 125 , 157 ] . The sensitivity and specifi city of all the diagnostic tests, but in particular the conventional tests, are highly dependent on the viral target, age of the patient, duration of symptoms prior to sample collection, sample collection methods, and the transport and storage conditions [ 1 , 39 , 48 , 49 , 85 , 95 , 118 , 127 , 131 , 164 ] . RADTs are generally the simplest tests to perform, many are waived tests under the Clinical Laboratory Improvement Amendments (CLIA), and results are generally available within 15-30 min. Despite these benefi ts, RADTS have limited utility due to the narrow scope of pathogens detected (RSV, FluA, and FluB) [ 125 ] , and modest to poor sensitivities [ 21 , 39 , 45 , 61 , 75 , 79 , 125 , 199 ] which can range from 50-90 % for RSV [ 47 ] and 10-85 % for infl uenza viruses depending on the comparator method. Overall, the specifi cities of RADTs are good [ 21 , 39 , 45 , 61 , 75 , 79 , 125 , 199 ] ; however, the specifi city for the detection of infl uenza A (H1N1) pdm09 was signifi cantly lower than previously reported [ 197 , 198 ] . RADTs generally perform better when testing pediatric samples since children shed higher titers of virus and for longer time periods than adults, especially the elderly [ 28 , 85 , 93 ] . DFAs detect a broader range of viruses (ADV, FluA, FluB, HMPV, PIV-1, PIV-2, PIV-3, and RSV) and can be performed in 30-60 min. The sensitivities of DFAs vary by virus, ranging from a high of approximately 60-85 % for RSV to a low of 50 % for ADV when compared to NAATs [ 116 , 125 ] . DFAs are generally very specifi c, although specifi city can be dependent on the level of technical expertise of the reader. Rapid cell culture (Quidel/Diagnostic Hybrids, Athens, OH) can detect ADV, FluA, FluB, PIV-1, PIV-2, PIV-3, and RSV and has demonstrated sensitivities that range from a high of > 80 % for some FluA strains to a low of 50 % for RSV [ 125 , 130 , 152 ] and excellent specifi cities of greater than 95 % when compared to NAATs. Rapid cell culture is generally positive within 48 h for > 90 % of the seven viruses detected. Depending on the cell lines used and antibodies available for confi rmation, traditional tube culture can have a broader scope of pathogen detection when compared to RADTs, DFAs, and rapid cell culture [ 125 ] . Traditional culture will identify ADV, enterovirus (EV), HMPV, FluA, FluB, PIV-1, PIV-2, PIV-3, RSV, and HRV, plus additional viruses associated with lower RTIs in immunocompromised patients, including CMV, HSV-1, HSV-2, varicella zoster virus (VZV). Often laboratories do not specifi cally screen for HRV by culture, although HRV is the most common respiratory virus detected and has been shown to cause signifi cant and serious disease in young, elderly, immunosuppressed patients, as well as patients with underlying chronic lung disease such as COPD and asthma [ 83 ] . In addition, many additional important viruses (229E-CoV, OC43-CoV, NL63-CoV, HKU-1-CoV, SARS-CoV, MERS-CoV), PIV-4, and potentially HBoV) that cause both URTIs and LRTIs are not routinely identifi ed by traditional culture [ 83 , 105 , 200 ] . Finally, due to time-to-virus-detection by traditional culture (generally 3-7 days for most respiratory viruses and 3-4 weeks for slow-growing viruses such as CMV), results are usually not available within a time frame (48 h) that could affect patient management (i.e., initiate appropriate antiviral therapy and/ or discontinue inappropriate antibiotic therapy). In summary, RADTs, DFAs, and rapid cell culture may provide results within a clinically relevant time frame but with limited pathogen scope and reduced sensitivity compared to NAATs. In addition, RADTs, DFAs, and rapid/traditional cell culture rarely detect more than one virus from a single sample. The standard methods for the detection of bacterial pathogens causing pneumonia are gram stain in combination with microbiological culture of lower respiratory tract specimens and blood. Often culture of respiratory specimens is not ordered on hospitalized patients and rarely performed in the outpatient setting. A gram stain result can be available within a few hours but results do not always correlate with culture [ 10 ] . Culture and antibiotic susceptibility results are usually available in 2-5 days after sample collection, and detection rates for pathogens are relatively low. A meta-analysis that evaluated 122 reports on CAP for the time period of 1966-1995 showed that a bacterial pathogen was only identifi ed in 18 % of the samples tested [ 68 ] . A urinary antigen test for S. pneumoniae offers a substantial improvement over culture, with a sensitivity of 82 % and a specifi city of 97 % in bacteremic adults [ 209 , 210 ] . However, in non-bacteremic adults and in children, both the sensitivity and specifi city are lower [ 210 ] . False-positive S. pneumoniae antigen tests have been reported relating to antibiotic interference. Legionella spp. are identifi ed by growth on buffered charcoal yeast extract agar [ 158 ] . The sensitivity of Legionella culture can vary signifi cantly from <10-80 % and DFA sensitivity from 25-70 % [ 158 ] . A urinary antigen test for L. pneumophila improves detection but is suboptimal since detection is limited to serogroup 1. For L. pneumophila serogroup 1 the sensitivity of the test varies from 70 -100 %. Most laboratories do not culture for Mycoplasma or Chlamydophila [ 140 ] . Traditionally, B. pertussis was identifi ed using culture on Bordet-Gengou media and/or DFA. However, the sensitivity of culture ranges from 12 -60 %, the sensitivity of DFA ranges from 11 -68 % [ 119 ] . Additionally, culture can take many days. Therefore, NAATS have become the gold standard for the rapid and sensitive (70-99 %) identifi cation of pertussis [ 119 ] . Serologic antibody testing is available for some of the respiratory pathogens and can provide supplemental information. However, due to a delay in the development of detectable IgM or IgG antibodies for certain pathogens (e.g., L. pneumophila , C. pneumoniae , B. pertussis ), usefulness for diagnosis in a clinically relevant time frame is very limited [ 17 , 151 , 158 , 221 ] . Shortcomings of serological testing include the timing of the serum samples, difficulty in obtaining appropriately paired serum samples, and the high background of IgG antibody prevalence in some adult populations [ 140 ] . Serologic diagnosis can be misinterpreted due to prior immunization or infections, such as in the case of infl uenza, and require demonstration of a signifi cant rise in antibody titers from initial to convalescent samples. Finally, persons with immune suppression may not develop antibodies or they may be of an insuffi cient level for detection, limiting the functionality of serology for monitoring vaccine response and for epidemiology studies to determine prevalence rates. Prior to the 2009 FluA(H1N1) pandemic, the infectious causes of CAP were mostly inferred based on clinical presentation which can be highly inaccurate since some bacteria, atypical pathogens, and many of the respiratory viruses cause illnesses with similar clinical symptoms [ 177 , 194 ] . One study demonstrated that physicians recognized infl uenza in only 28 % of hospitalized children and 17 % of nonhospitalized children with laboratory-confi rmed infl uenza when the diagnosis was based only on clinical symptoms [ 177 ] . Most diagnostic testing was limited to RADTs for FluA, FluB, and RSV as few hospitals offered comprehensive DFAs, viral culture, or laboratory-developed NAATs. The superior ability of NAATs to rapidly and accurately detect both known and novel pathogens was best exemplifi ed during the chaos of the 2009 FluA H1N1 pandemic [ 18 , 39 , 79 , 197 , 198 ] . Fortunately, at the start of the pandemic two NAATs were FDA-cleared for the detection of infl uenza viruses, the Prodesse PROFLU+ (Hologic, San Diego, CA) for the detection and differentiation of FluA and FluB ( [ 124 ] ; and one highly multiplexed NAAT: the Luminex xTAG RVP Respiratory Virus Panel (Luminex Molecular Diagnostics, Toronto, Canada) [ 113 , 114 , 143 ] . The xTAG assay enabled laboratories to detect FluA(H1N1)pdm09 and differentiate the seasonal FluA H1N1 (FluA-H1) and seasonal FluA H3N2 (FluA-H3), but also identify many other circulating viruses [ 79 , 78 ] . As shown in Fig. 52 .2 , the number of samples positive for a respiratory virus increased dramatically with the use of the highly multiplexed xTAG RVP assay (64 %) compared to traditional test methods, including RADTS (17 %), DFA (18 %), and rapid cell culture (31 %) [ 79 ] . Interestingly, mixed viral infections containing up to four viral pathogens were identifi ed in hospitalized patients [ 79 ] . Similarly, other studies have shown that when broad test panels are used more than one virus will be identifi ed in 3-30 % of respiratory samples [ 8 , 166 ] . Although the significance of mixed viral infections needs to be more clearly defi ned, the clinical impact needs to be considered as potentially severe in patients with comorbidities, immunosuppression, or other critical illnesses. During respiratory virus seasons with high infl uenza rates, patients with the same pathogen often are placed in hospital rooms together (cohorting) due to limited private rooms [ 19 , 39 , 40 , 62 , 126 , 155 , 165 , 217 , 219 ] . The consequences of a second viral infection in an already seriously ill hospitalized patient could be substantial, indicating that comprehensive test panels are essential in this setting. Consequently, there has been a major shift in testing practices as numerous FDA-cleared single-and multi-analyte molecular tests for the detection of respiratory pathogens have become available (Table 52. 2 ). Viral respiratory pathogens are particularly suited for detection using NAATs since the number of targets is relatively limited and the detection of a respiratory virus is generally considered diagnostic, although asymptomatic carriage of certain respiratory viruses has been reported in several studies [ 2 , 14 , 104 , 181 ] . For the majority of viral and atypical bacterial respiratory pathogens, NAATs offer enhanced sensitivity over culture, RADTs and DFAs (see Tables 52.2 and 52.3 for references), and the specifi city varies with the target and assay design but is generally very high. NAATs also are suited for detection of respiratory pathogens that are not routinely or easily cultured (e.g., C. pneumoniae , M. pneumoniae , HBoV, HMPV, and PIV-4), for pathogens dangerous to culture (e.g., SARS-CoV, MERS-CoV), and for pathogens where the time-to-detection by traditional testing is often too delayed to impact patient care (e.g., infl uenza and CMV by cell culture). The expanded scope of pathogen detection from a previous low of three viral pathogens detected by RADTs to 17 viral and three bacterial pathogens detected by NAATs greatly enhances the clinical laboratory's diagnostic capabilities. [ 35 , 56 , 59 , 107 , 129 , 163 , 178 , 195 , 196 , 198 , 199 ] The data derived from studies utilizing comprehensive viral and bacterial NAATs has and will continue to provide invaluable insights into the clinical manifestations of viral and bacterial infections, signifi cance of mixed viral infections, and surprisingly the realization that viruses can colonize a host without overt disease. Aside from the use of RADTs during infl uenza season, RTI diagnostic testing including viral DFAs and culture, bacterial culture, NAATs, serologic testing for the atypical pathogens, and urinary antigen testing for S. pneumoniae and L. pneumophila are still underutilized in the outpatient setting [ 10 , 189 ] . Therefore, treatment of patients with CAP is generally empiric and based on guidelines by the American Thoracic Society and IDSA [ 146 ] rather than on a confi rmed laboratory diagnosis. Antibiotic selection must cover both the most prevalent bacterial pathogens and the atypical pathogens. Despite the high prevalence of viral infections, approximately 22.6 million (55 %) out of 41 million antibiotic prescriptions were prescribed for viral lower and upper RTIs, despite the fact that a bacterial etiology was highly unlikely [ 82 ] . Conversely the identifi cation of the viral pathogen can lead to the administration of an appropriate antiviral. For example, during the early weeks of the 2009 infl uenza A H1N1 pandemic, four different infl uenza viruses were circulating with varying antiviral susceptibility patterns. According to surveillance data provided by the Center for Disease Control and Prevention (CDC, Atlanta, GA), FluA-H1 strains demonstrated >99 % resistance to the fi rst line therapeutic oseltamivir, a neuraminidase inhibitor, and susceptibility to adamantine, FluA-H3 was oseltamivir-susceptible and >99 % adamantine-resistant, FluA(H1N1)pdm09 was oseltamivirsusceptible and >99 % adamantine-resistant; FluB was oseltamivir-susceptible and adamantine-resistant. Therefore, the identifi cation of what specifi c strain of infl uenza virus was causing the infection of specifi c patients was essential to ensure proper drug selection, especially in high-risk or critically ill patients. Additionally, the more appropriate use of infl uenza antivirals can be achieved when an accurate, rapid diagnosis is made. Recent studies demonstrated that rapid testing permitted the timely administration of oseltamivir [ 229 ] and allowed for a more rapid discontinuation of treatment in persons without documented infl uenza [ 191 ] . Finally, new viral therapeutic agents for respiratory viruses other than infl uenza are in development and/or in clinical trials [ 171 , 233 ] . Proper administration of these new agents will depend on the laboratory providing accurate tests that detect a broad range of viral pathogens [ 189 ] . For HAP and VAP, initial empiric therapy choices may be standardized and initiated based on patient clinical status, underlying disease, and/or risk for infection with a multidrugresistant pathogen. Initial therapy often is inadequate, thereby extending the course of the disease and increasing morbidity, mortality, and hospital length of stay. The mortality rate in ICU pneumonia cases ranges from 20-30 % when initial therapy was adequate, to 50-80 % when initial therapy was inappropriate and changed after culture results were obtained [ 112 ] . Furthermore, inadequate and/or unnecessary broad spectrum antibiotic therapy can enhance the spread of drug-resistant pathogens within institutional settings and increase the risk of hospital-acquired infections such as Clostridium diffi cile , MRSA, and vancomycin-resistant enterococci. Comprehensive NAATs provide key information not only for antiviral therapy selection but can also aid in restricting antibiotic use to those circumstances where antibiotic therapy is appropriate and in promoting switches to targeted specifi c therapies, thus reducing the use of broad spectrum antibiotics when not indicated [ 170 , 142 , 189 ] . This practice is in keeping with the goals of antibiotic stewardship, especially considering the steady and critical rise of antibiotic resistance and limited or no options available for the treatment of multidrug or pan-resistant bacterial infections. The burden of nosocomial infections can be signifi cant, incurring additional costs for supplemental diagnostic tests, extended hospitalization, and increased morbidity and mortality [ 19 , 40 , 62 , 126 , 155 , 217 , 219 ] . Therefore, rapid diagnostic tests are needed to identify infected patients upon admission, thereby preventing nosocomial transmission by facilitating isolation and appropriate cohorting decisions [ 165 , 206 ] . Studies have documented signifi cant nosocomial transmission of ADV, infl uenza, RSV, HMPV, PIV, and HRV in hospital units, chronic care facilities, and pediatric units [ 19 , 40 , 62 , 126 , 155 , 217 , 219 , 232 ] . During the height of RSV season, when prevalence can be >50 %, high numbers of hospital admissions often require the cohorting of RSVpositive children due to a lack of private rooms. However, limiting diagnostic testing to RSV alone in a cohorting scenario could put other seriously ill children at risk for acquisition of a second viral infection with other pathogens such as HMPV or HRV [ 80 ] . The rapid identifi cation of health care facility-acquired Legionella infection is essential so that the environment source can be identifi ed and eradicated, thus preventing further transmission. In addition, PCR techniques are used to proactively routinely screen potential environmental sources. The identifi cation of a wide range of viral pathogens is essential for epidemiologic surveillance and establishes both seasonal and population patterns which can serve as excellent indicators for predicting immunization scheduling (e.g., infl uenza), or for administering preventive measures (e.g., RSV immune globulin). Previously, such surveillance was done by state Departments of Health or on a national level by the CDC. Comprehensive NAATs now enable local laboratories to monitor in real time viral prevalence and provide to their clinicians and health care facilities regular updates on circulating viruses. Testing decisions should use local data and additional resources and epidemiology information provided on the CDC web site ( http://www.cdc.gov/fl u/ ). A study by S. Wong et al. demonstrated that the use of a multiplex NAAT (17 viruses) identifi ed a virus in 59 % of the outbreaks and 29 % of the outbreak specimens that were negative using DFAs and a limited number of individual NAATs (ten viruses) [ 226 ] . Overall, the detection rate increased from 72-91 % for outbreaks and from 47-56 % for outbreak specimens. Comprehensive testing can identify reemerging or new emerging viral pathogens, as was the case during the infl uenza A H1N1 2009 pandemic. Additionally, NAATs have been a key component in understanding both the epidemiology and features of large outbreaks of pertussis-like illness [ 190 ] . For example the large percentage of cases (29 %) of B. holmseii identifi ed in an outbreak in Ohio in 2010-2011 was in contrast to some previous reports where the frequency of detection was very low [ 190 ] . The USA has seen peaks of pertussis activity every 3-5 years, with increasing cases since 1980. Accurate detection of pertussis is essential to better control the spread of disease from a public health standpoint through antimicrobial prophylaxis of asymptomatic household contacts, children less than 1 year of age, pregnant women in their third trimester, persons with preexisting conditions that are at risk for the development of severe respiratory failure, and all contacts in high-risk settings ( http://www.cdc.gov/pertussis/outbreaks/pep.html ). The recovery of respiratory pathogens is highly dependent on using the appropriate sample type and collection methods [ 139 ] . Laboratories using commercial FDA-cleared assays should refer to the manufacturer's package information to determine what sample types have been validated for use with the specifi c test (Table 52 .2 ). The use of alternate samples types is permitted after the laboratory has performed their own validation studies that establish acceptable performance characteristics when testing the alternate sample type. Applicable upper respiratory tract specimens for viral, C. pneumoniae , and M. pneumoniae testing include nasopharyngeal (NP) washes, NP aspirates, NP swabs, and midturbinate swabs placed in viral transport media [ 1 , 48 , 49 , 95 , 118 , 131 , 164 , 223 ] . Oropharyngeal swab specimens are less sensitive (54 %) than either NP swabs (73 %) or NP wash specimens (85 %) due to the substantially lower levels of virus present in the oropharynx than the nasopharynx [ 131 ] . However, the combined use of nasal-oropharyngeal swabs can enhance the recovery of both avian infl uenza and SARS-CoV [ 49 ] . NP fl ocked synthetic swabs should be used in lieu of traditional synthetic NP swabs since fl ocked NP swabs yield a greater recovery of viral pathogens, with sensitivity comparable to NP wash specimens [ 1 , 48 , 95 ] . The rates of positivity for B. pertussis by real-time PCR were shown to be comparable when specimens were collected with either NP rayon swabs on aluminum shafts in Amies gel with charcoal or NP fl ocked swabs in universal transport media [ 6 ] . Lower respiratory tract (LRT) samples appropriate for viral pathogens, C. pneumoniae , M. pneumoniae , L. pneumophila , and bacterial pathogens include induced sputum, bronchial alveolar lavages, bronchial washings, protected brushes, and Combicath specimens. Studies that examined the detection of FluA(H1N1)pdm09 found that in seriously ill patients requiring intensive care, upper respiratory tract samples can be negative while LRT samples are positive [ 120 , 123 , 156 , 230 ] . Additional factors that infl uence pathogen recovery include the time of sample collection after the onset of clinical symptoms and the age of the patient (children tend to shed higher titers of virus and for longer periods of time than adults). Therefore, for optimal detection, samples should be collected within 3 days for adults and within 5 days for children after the onset of symptoms [ 39 , 85 , 95 , 120 , 123 ] . Samples should be transported to the laboratory as soon as possible, preferentially on wet ice or refrigerated (2-8 °C) if testing will be performed within 48 h. If testing is delayed, the samples should be stored at −80 °C. Multiple freezethaws should be avoided as this process can decrease pathogen titers. Target lysis in a stabilizing matrix to prevent target degradation by deoxyribonucleases (DNases) and/or ribonucleases (RNases), followed by isolation and purifi cation of the nucleic acids (NAs) are essential and critical steps of every NAAT. This is particularly important for respiratory samples that can be highly viscous and contain inhibitory substances and enzymes that destroy the target NAs. Some sample types may require a pretreatment with proteinase K or a similar enzyme. Highly effi cient commercial NA extraction systems ensure suffi cient NA recovery and the removal of inhibitory substances that could result in ineffi cient or no amplifi cation of the target NAs. Presently, the majority of NA extraction systems use a chaotropic agent to lyse viral particles or bacterial cells, silica particles or a membrane to capture the released NAs, and a series of wash steps to remove inhibitory substances. NAs are generally eluted in either RNase/ DNase free water or a stabilizing buffer such as EDTA-Tris. Although NA extraction can be performed manually using for example spin columns, the majority of laboratories currently use automated platforms that can extract as few as one sample at a time or more than 96 samples in microwell plate formats. Many NAATs have been FDA-cleared with specifi c extraction platforms or methods and laboratories should be aware that the substitution of another extraction platform or method constitutes a major change in the assay protocol. From a regulatory perspective, if the extraction procedure is modifi ed or changed then the entire test is now considered an LDT. Laboratories must be compliant with all applicable state and federal CLIA standards, and may choose to comply with the College of American Pathologists regulations to meet state or federal regulatory requirements. Many amplifi cation and detection methods are used in the current FDA-cleared assays (Table 52. 2 ) and additional assays that are not FDA cleared but may be Conformité Européenne (CE) marked for use as an in vitro diagnostic device (IVD) in Europe (Table 52. 3 ). Amplifi cation methods include traditional reverse transcription polymerase chain reaction (RT-PCR), PCR, real-time RT-PCR and PCR, RT-PCR and primer extension, nested PCR, amplicon rescued multiplex PCR (ARM-PCR), and isothermal amplifi cation such as nucleic acid sequence based amplifi cation (NASBA), helicase-dependent amplifi cation (HAD), nicking enzyme amplifi cation reaction (NEAR), and loop mediated amplifi cation (LAMP). Primers sets can be broad range (e.g., family), short range (e.g., genus), or pathogen-specifi c (e.g., genus and species). Targets may be single or multiple copy and include genomic RNA, or DNA, or messenger RNA. Detection technologies utilize fl uorogenic intercalating dyes, fl uorogenic probes (Taqman, fl uorescence resonance energy transfer [FRET] hydridization, molecular beacons, scorpions, locked nucleic acid [LNA]), arrays (liquid bead, gold nanoparticles, or solid chip), electrochemicalbased methods, melt curve analysis, lateral fl ow, or simple turbidity. Tests vary considerably with the number of targets detected, ranging from one pathogen target plus an internal control (IC) to 20 targets plus an IC. They differ in which targets are detected (viral and/or bacterial) and if the tests are able to detect and differentiate various types within a virus family (e.g., PIV-1, -2, -3, and -4) (Tables 52.2 and 52.3 ). Platforms can be all inclusive with NA extraction, amplifi cation, and detection performed in one cartridge (e.g., GeneXpert, Cepheid, Sunnyvale, CA; cobas Liat System, Roche Molecular Systems/Iquum, Marlborough, MA), in one pouch (Film Array, BioFire/bioMérieux, Salt Lake City, UT), or one chamber of a multi-test wheel cartridge (Simplexa Direct, Focus Diagnostics, Cypress, CA). Testing can be performed using modular systems that incorporate NA extraction with amplifi cation but a separate unit for detection (e.g., Verigene, Nanosphere, Northbrook, IL), modular systems that separate isolation, from amplifi cation combined with detection (Simplexa, Focus Diagnostics,; ProFlu+, Gen-Probe, San Diego, CA; Lyra, Quidel, San Diego, CA) and systems where isolation, amplifi cation, and detection are all performed separately (xTag RVP, Luminex, Austin, TX; eSensor XT-8 System, GenMark Diagnostics, Carlsbad, CA; Infi niti RVP Plus, Autogenomics, Vista, CA; Resplex II, Qiagen, Valencia, CA). Only a limited number of tests are FDA-cleared for the detection of bacterial pathogens. One highly multiplexed test, the FilmArray Respiratory Panel (BioFire/bioMérieux) tests for 17 viral pathogens and three bacterial pathogens, C. pneumoniae , M. pneumoniae , and B. pertussis . One additional assay is FDA-cleared for the detection of M. pneumoniae , the illumi gene Mycoplasma Assay (Meridian Biosciences, Inc, Cincinnati, OH). Two addition assays are FDA-cleared for the detection of B. pertussis , the illumi gene Pertussis assay (Meridian) and the Amplivue Bordetella assay (Quidel, San Diego, CA). Time-to-results for the FDA-cleared assays ranges from 15 min to approximately 12 h depending on the platform, with the most rapid results (< 1.5 h) for the all-inclusive cartridge/pouch based tests. Technical hands-on time varies from < 2 min to approximately 3 h. Currently, most NAATs are rated as CLIA moderate to high complexity. In January 2015, the fi rst waived NAAT under CLIA was cleared by the FDA, the Alere i Infl uenza A&B test (Alere Scarborough, Scarborough, ME). To perform the test, a sample receiver and test base are inserted into the Alere i instrument (Alere). After a 3 min heating step, the sample is eluted from the nasal collection swab directly into the sample receiver buffer. The transfer cartridge is used to transfer the sample to the test cartridge, where NEAR-amplifi cation and detection occur in approximately 10 min [ 11 , 12 , 35 , 162 ] . For comprehensive diagnosis of CAP and to rapidly identify pathogens associated with HAP and VAP, additional tests are needed that target the main bacterial pathogens [ 63 ] . The Research Use Only (RUO) Unyvero System (Curetis, Stutgart, GR) has an assay developed as an aid for the diagnosis of bacterial pneumonia. The specimen is preprocessed in Unyvero L4 Lysator, and then added to the assay-specifi c cartridge which is then inserted into the Unyvero A50 analyser. All steps are controlled by the Unyvero C8 Cockpit. The assay detects the major bacterial pathogens ( Acinetobacter baumanii , Enterobacter spp. Escherichia coli , Klebsiella oxytoca , Klebsiella pneumoniae , Haemophilus infl uenzae , Moraxella. catarrhalis , Morganella morganii , Proteus spp., S. aureus , Pseudomonas aeruginosa , Serratia marcescens , S. maltophilia , S. pneumoniae ), the atypical pathogens (C. pneumoniae , L. pneumophila ), and one fungal pathogen ( Pneumocystis jiroveci ) known to cause CAP, HAP, and VAP. In addition, the assay will detect 18 genes associated with the major categories of antibiotic resistance. Time-toresults is approximately 4-5 h. The assay serves as a preliminary screen to be followed by culture and traditional antimicrobial susceptibility testing. Preliminary studies demonstrated that the assay detected more pathogens than routine culture. The Unyvero system detected numerous resistance markers and allowed for a change in empiric antibiotic therapy within 5-6 h for 67 % of the patients tested [ 103 , 201 ] . The RUO Abbott Plex-ID system (Abbott, Abbott Park, IL) is comprised of broad range PCR or RT-PCR and Electrospray Ionization Mass Spectrometry (PCR/ESI-MS) for pathogen detection [ 36 , 37 , 44 , 55 ] . Following NA extraction, PCR and/or RT-PCR is performed in a microwell plate using multiple primer pairs, with one primer set per well. Following amplifi cation, the automated platform performs post-PCR desalting, purifi cation, and high-resolution mass spectrometry using ESI-MS. The raw spectra are analyzed and calibrated with an internal mass standard. Spectral analysis determines the nucleotide base composition of the single-stranded oligonucleotides complementary to the initial target. To evaluate the relative concentration of the target or targets present, a semiquantitative value can be obtained by comparing the peak heights with the internal PCR calibration internal mass standard present in every well. The initial Plex-ID (Ibis T5000) system has been replaced by the Abbott IRIDICA RUO system (Abbott) that is comprised of PLEX-ID SP (nucleic acid extraction platform), PLEX-ID FH (liquid handler for assay setup), and a new version of the PLEX-ID PCR/ESI-MS platform. Time-to-results is <8 h. PCR-or RT-PCR/ESI-MS has been used to detect and identify a variety of respiratory viruses, infl uenza subtypes, bacteria, and fungi associated with RTIs ( [ 88 , 159 , 207 , 214 , 215 ] ; Huttner et al. 2014). Overall, NAATs for respiratory viral and the atypical bacterial pathogens are highly sensitive (85 -100 %) and very specifi c (>95 %) when samples are collected shortly after the onset of clinical symptoms (see references in Tables 52.2 and 52. 3 ). Assays can detect mixed infections [ 79 ] and a broad range of viral types within a family [ 34 ] . Performance results from clinical trials for FDA clearance and from investigatorinitiated studies need to be reviewed carefully when evaluating an assay because many factors can affect the overall results, such as patient population and age, testing conditions, specimen collection factors, storage time from sample collection to testing, and comparator method used in the analysis. Similarly, results obtained in different studies can vary signifi cantly for assays and targets, depending on the study design (see references in Tables 52.2 and 52.3 ) . Numerous studies have demonstrated that not all targets within a particular assay are detected with the same sensitivity. NAATs also have certain limitations. Due to the complexity of primer and probe designs and interactions, highly multiplexed NAATs can sometimes be less sensitive than individual NAATs [ 70 , 166 , 167 ] . Reduced analytical sensitivity, however, does not always correlate with reduced clinical sensitivity since viral quantity in clinical samples, depending on the virus and timing of sample collection, are often much higher than the limit of detection of the assays. NAATs often are less sensitive for viruses with multiple serotypes, such as ADV [ 37 , 74 , 113 , 133 ] . Decreased performance for the detection of ADV can be clinically signifi cant, particularly when testing samples from immunosuppressed patients (e.g., transplant patients) for whom ADV infection has a high mortality rate if not treated. For highrisk patients, laboratories may elect to supplement testing with either a more sensitive, broadly reactive ADV-specifi c assay or with cell culture [ 25 , 62 , 148 , 173 ] . Many of the assays cannot distinguish between HRV and EV due to the fact that the assays target the 5′ UTR which is genetically similar for the two viruses [ 113 ] . The performance of the assays, in particular for RNA viruses, also may be affected by sequence mutations that occur over time. These mutations can result in primer/probe mismatches that decrease assay sensitivity, result in a total lack of target amplifi cation and detection, or result in cross reactivity [ 153 ] . Any modifi cations to the assays to accommodate such genetic changes would have to be cleared by the FDA. In highly multiplexed assays, revalidation can require extensive assessment of all target interactions, thus making changes extremely diffi cult. The FDA-cleared assays for the detection of B. pertussis target the multicopy IS481 gene. This gene is found not only in B. pertussis (50-238 copies/cell) but also in B. holmseii (8-10 copies.cell) and in 1-5 % of the strains of B. brochioseptica [ 190 ] . Therefore, the assays are not specific for B. pertussis and alternative targets must be tested to differentiate the three species and also to detect B. parapertussis [ 89 , 190 , 216 , 225 ] . Additionally, pseudo-outbreaks of pertussis have been described, indicating that great caution must be used not only in performing the NAAT but also in the collection of test samples, particularly in areas where vaccine is administered. Finally, due to the short time of localization of the atypical bacterial pathogens to the URT, the detection of these pathogens may require a combination of various sample types and various test methods, including NAATs, serology, and antigen testing, to provide the most sensitive results. The advantages of NAATs compared with traditional testing methods include improved sensitivity, not needing a viable organism for detection, broader scope of pathogens identifi ed, and the ability to detect mixed infections. These same advantages can also raise issues with the interpretation of results. Until recently the detection of any respiratory virus had been considered signifi cant. Several studies have shown that respiratory viruses can be detected in asymptomatic patients [ 2 , 14 , 104 , 181 ] . One study found that NAATs identifi ed a virus in 83 % of specimens from symptomatic children, but also detected a virus in 42 % of specimens from children without symptoms [ 2 ] . Another study demonstrated similar colonization with CoV (7.6 %) in symptomatic hospitalized children versus (7.1 %) in an asymptomatic outpatient control population. The overall prevalence of CoV or the types of CoV was not signifi cantly higher among hospitalized children than controls. Respiratory viruses in NP swabs were identifi ed from both asymptomatic and symptomatic solid organ transplant recipients early after transplantation [ 14 ] . The data suggest that due to the high prevalence of positive results in children and immunocompromised patients without symptoms, results should be interpreted cautiously, and in the context of clinical presentation, radiographic fi ndings, and other laboratory tests. Additionally, clinicians must be aware that NAATs will detect nucleic acids lingering from a previous infection and that samples submitted for assessment of therapeutic response may remain positive for days to weeks after treatment due to the presence of nonviable organisms and not due to treatment failure. In these situations culture or quantitative NAATs (see Future Directions below) may provide the best option. With the increased use of highly multiplexed respiratory virus assays, a variety of mixed viral infections are detected and the clinical importance of each virus is not always evident. Nonviable virus from a previous infection may be detected, making it impossible to determine which or if all viruses contribute to the current illness. Test reports need to explain what viruses are included in the NAAT panel, sensitivity and specifi city of the test, and that a negative result does not preclude infection with a specifi c pathogen due to many factors that can lead to decreased assay sensitivity. Aside from the detection of the atypical pathogens and Bordetella spp. the detection of other bacterial pathogens, such as those included in the Unyvero test, directly from clinical samples raises several interesting questions that need to be addressed: (1) How do we differentiate between colonization and infection so as not to promote overuse of antibiotics? Are quantitative assays necessary or can assay cut off values be established at clinically relevant thresholds? (2) How many pathogens need to be included in a screening test? The detection of the broad scope of potential gram-positive and gram-negative bacterial pathogens is limited by multiplexing capabilities. Should these assays detect at a minimum those pathogens with the highest clinical impact or those diffi cult to treat? (3) How can we detect a broad range of resistance mechanisms, some of which do not have genetic markers (such as porin down-regulation in Pseudomonas spp.)? (4) Can we trust a positive result to direct antibiotic therapy? (5) Can we trust a negative result when there is the possibility of the presence of unknown resistance mechanisms? (6) Do we need to link a resistance marker to a specifi c bacterial target? For example, how do we interpret a result positive for a specifi c resistance gene when we do not detect the organism in which it would reside? (7) Will this type of testing provide actionable results, i.e., will this change clinical practice? The answers to these questions will only be resolved during clinical trials that compare NAAT results to classic microbiology testing, clinical practice, and patient outcomes. However, the future of testing may be a combination of multiplexed NAAT viral and bacterial screens. Laboratories must consider multiple factors in selecting the most appropriate NAAT or in developing testing algorithms (Table 52 .4 ) [ 60 ] . Considerations include patient population(s), FDA status of the NAAT and the implications for regulatory issues, platform type, test complexity and technical expertise required, turnaround time, testing volumes, batch vs single unit testing, and the number and type of pathogens detected. The higher costs of NAATs can easily be offset by replacing the less sensitive test methods or by testing on site in lieu of referral to a reference laboratory [ 60 , 144 ] . Additionally costs can be offset by other demonstrated benefi ts, such as improvements in patient care and fi nancial outcomes, including 30 % reduction in antibiotic use, up to 20 % reduction in unnecessary diagnostic tests and procedures, and 50 % reduction in hospital days [ 9 , 22 , 82 , 92 , 115 , 120 , 123 , 142 , 170 , 191 , 227 , 229 ] . To achieve these benefi ts NAATs should be performed within 24 h of sample collection so that results are available within a clinically relevant time frame. With the advent of single unit cartridge/ pouch based tests that require minimal hands-on time and very minimal molecular technical expertise, all size laboratories can perform NAATs on all shifts. Considering the impact of global travel, comprehensive and highly specifi c NAATS should be performed year round and not limited to specifi c seasons. Although the positive predictive value of these tests remains high during times of low viral prevalence, laboratories should consider confi rmatory testing when a virus is detected during an unusual time period. Some pathogens are more prevalent in specifi c groups (e.g., RSV and HMPV in children and the elderly), but limiting testing to specifi c age groups will miss clinically relevant disease in other patient populations [ 64 , 83 ] . Infections with these pathogens can also sometimes have atypical presentations, such as pericarditis due to HMPV in an otherwise healthy adult [ 97 ] . Therefore, age may be useful in triaging initial testing but should not govern the fi nal scope of what viruses are included in diagnostic testing. In addition, if step wise testing is considered based on risk factors such as age or immune status, coinfections that could lead to serious nosocomial transmission in health care settings should not be missed. Unexpected local, national, and international events, such as the H1N1-2009 pandemic can change our testing algorithms and laboratories must be prepared to adapt quickly to such events. Kit positive and negative controls, ICs, and external controls should be used to verify the performance of the reagents and to ensure no inhibitory substances remain after extraction that could lead to poor amplifi cation, reduced assay sensitivity, and false-negative results [ 77 ] . Controls should be tested in accordance with regulatory requirements as outlined by CLIA, CAP, and state or other federal regulatory agencies, and in accordance with the manufacturer's instructions. Ideally all controls should go through the same process as the patient sample. ICs are best added at the NA extraction step to ensure effi cient recovery of NAs. ICs added after extraction will just confi rm the amplifi cation effi ciency and an external extraction control must be used unless the extraction method has demonstrated negligible inhibition (generally <1 %) for the sample types tested. During amplifi cation and detection, the IC is essential to demonstrate a lack of amplifi cation failure or decreased effi ciency. External positive and negative controls (not provided in the kit) must be used to verify each new lot and/or shipment of reagents. Each analyte of the multiplex must be verifi ed individually in either a single reaction or as a component of a pooled control. Daily positive (individual or pooled) and negative controls must be run thereafter if batch testing is performed. Rotating controls after lot/shipment validation is acceptable. Tests using a single unit cartridge/pouch that contain a procedural control (IC or process control) do not require external controls to be run with each individual cartridge/pouch once the performance of the procedural control has been verifi ed. External positive controls for each analyte and negative controls are only required for verifi cation of each new lot/shipment or at a minimum once per month. Laboratories must ensure proper procedures to prevent both sample and amplicon cross contamination that could cause false-positive results. Laboratories need to interpret negative results and IC values in the context of the presence or absence of potential nucleic acid degradation and amplification inhibition. Laboratories are responsible to continually assess the performance of their assays to ensure that over time, the performance has not declined due to factors such as genetic shifts in the target analytes. Finally, ongoing assessment of technical competency and participation in proficiency testing programs are essential to ensure high-quality performance and results. Both virus type and the amount of virus present (viral load) can signifi cantly impact the clinical characteristics and clinical course of RTIs. Quantitative detection of viral respiratory pathogens can help to assess the dynamics of viral proliferation, better understand viral pathogenesis, and permits a means to evaluate the signifi cance of coinfections. Since NAATs detect both viable and nonviable virus, monitoring patients for treatment response with qualitative testing provides little information as tests may remain positive for days even with successful therapy. Quantitative tests that demonstrate a decline in viral load during therapy more accurately assess patient response (Fig. 52.3a ) and the failure to see a decline ( Fig. 52.3b ) would potentially indicate earlier a need to consider alternative therapies. This information is especially important for critically ill patients and immunosuppressed patients. Finally, viral load assays provide important information in the assessment of new antiviral agents in FDA clinical trials. Future assay development should consider quantifi cation of the viral targets. Antiviral resistance to neuraminidase inhibitors can be assessed both phenotypically and genotypically [ 84 , 161 , 187 ] . Neuraminidase inhibition assays detect decreases in susceptibility by determining the 50 % inhibitory concentration (IC 50 ). However, these assays require growth of the virus and the presence of quasi-species can lead to unreliable results. Alternatively, genotypic assays are easier and identify known resistance mutations. However, newly identifi ed mutations require phenotypic confi rmation. Although no molecular assays are FDA-cleared for infl uenza resistance testing, several methods are used including traditional Sanger sequencing, pyrosequencing, PCR genotyping assays, and next-generation sequencing (NGS) [ 84 , 161 ] . Pyrosequencing is currently the method of choice since the method is fast, has a high throughput, is sensitive (can detect a mutation if present in 10 % of the population), can assess multiple known mutations (e.g., H275Y mutation found in resistant H1N1-2009 strains) as well as unknown mutations and polymorphisms [ 52 -54 ] . NGS has the added advantage of generating longer sequence lengths and has identifi ed new genetic mutations associated with neuraminidase resistance. Laboratories should consider offering resistance testing in seasons where circulating strains may have varying resistance patterns (for example, H1N1 in 2007-2008 that demonstrated variable oseltamivir susceptibility), especially for patients at high risk to develop severe disease (e.g., pregnant or immunosuppressed) [ 38 ] . In addition, screening for resistance is indicated in seriously ill patients who continue to shed virus and are not clinically improving after prolonged antiviral therapy. Over the last decade the development of NGS has transformed a labor-intensive slow process into a real-time method with applicability to respiratory diagnostics. The complexity of NGS is beyond the scope of this chapter but the use of NGS will continue to evolve in the clinical laboratory, particularly in light of easy-to-use bench top sequencers such as the Ion Torrent Personal Genome Machine (PGM) (Life Technologies, Carlsbad, CA) and the MiSeq (Illumina, San Diego, CA). Already NGS is used to detect and identify respiratory pathogens, resistance and pathogenicity markers, genetically characterize viruses, explore the respiratory microbiome, and understand the epidemiology of respiratory pathogens [ 169 ] . With new emerging technologies and simple methods to perform the required bioinformatics, this testing will increasingly become part of routine diagnostics. The IDSA Diagnostics Task Force report: "Better Tests: Better Care: Improved Diagnostics for Infectious Diseases" highlighted the importance of diagnostic testing in the management of infectious diseases [ 27 ] . Likewise, the 2013 CDC [ 31 ] report "Antibiotic Resistance Threats in the US" states that both the development of new drugs and new diagnostics are essential to combat the threat of multiple-drug-resistant pathogens [ 30 ] . The incorporation of NAATs into routine practice for the diagnosis of infectious diseases will continue to grow, bringing new advanced technologies that allow the rapid and accurate detection of viral, bacterial, and fungal respiratory pathogens. Comparison between pernasal fl ocked swabs and nasopharyngeal aspirates for detection of common respiratory viruses in samples from children Detecting respiratory viruses in asymptomatic children Comparative evaluation of the nanosphere verigene RV+ assay and the Simplexa Flu A/B & RSV kit for detection of infl uenza and respiratory syncytial virus Guidelines for the management of adults with hospital acquired, ventilator associated, and hospital associated pneumonia Comparison of 4 PCR assays for the detection of viral pathogens in respiratory specimens Comparison of rates of positivity for Bordetella pertussis by real-time PCR between specimens collected with rayon swabs on aluminum wire shafts in Aimes gel with charcoal and specimens collected with fl ocked swabs in universal viral transport medium during an epidemic Comparison of the Luminex xTAG RVP Fast assay and the Idaho Technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital Evaluation of commercial ResPlex II v2.0, MultiCode-PLx and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults Clinical and fi nancial benefi ts of rapid detection of respiratory viruses: an outcomes study Diagnostic tests for agents of community acquired pneumonia Multicenter clinical evaluation of the novel Alere i Infl uenza A&B isothermal nucleic amplifi cation test Evaluation of the Alere i Infl uenza A&B nucleic acid amplifi cation test by use of respiratory specimens collected in viral transport medium Comparison of clinical features of pediatric RSV and human metapneumovirus infections Asymptomatic and symptomatic respiratory virus infection detected in naso-pharyngeal swabs from solid organ transplant recipients early after transplantation Evaluation of the combination of the NucliSENS easyMAG and the EasyQ applications for the detection of Mycoplasma pneumonia e and Chlamydia pneumoniae in respiratory tract specimens Comparative evaluation of the Seegene Seeplex RV15 and real-time PCR for respiratory virus detection Rapid-test sensitivity for novel swine-origin infl uenza A (H1N1) virus in humans An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility Near-point-of-care administration by the attending physician of the rapid infl uenza antigen detection immunochromatography test and the fully automated respiratory virus nucleic acid test: contribution to patient management Respiratory syncytial virus detection by Remel Xpect, Binax Now RSV, direct immunofl uorescent staining, and tissue culture Relative impact of infl uenza and respiratory syncytial virus in young children Detection of respiratory viruses in sputum from adults by use of automated multiplex PCR Comparison of two commercial molecular assays for simultaneous detection of respiratory viruses in clinical samples using two automated electrophoresis detection systems Real-time qualitative PCR for 57 human adenovirus types from multiple specimen sources Comparison of three commercial RT-PCR systems for the detection of respiratory viruses Better tests, better care: improved diagnostics for infectious diseases Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults Clusters of acute respiratory illness associated with human enterovirus 68 -Asia, Europe, and United States Diagnosis and management of Q fever -United States, 2013: recommendations from CDC and the Q Fever Working Group Antibiotic resistance threats in the United States NASBA and other transcription-based amplification methods for research and diagnostic microbiology Middle east respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease Broad reactivity of the Luminex xTAG Respiratory Virus Panel (RVP) assay for the detection of human rhinoviruses Performance of the molecular Alere i Infl uenza A&B test compared to Xpert Flu A/B Reverse transcription polymerase chain reaction and electrospray ionization mass spectrometry for identifying acute viral upper respiratory tract infections Rapid identifi cation viruses from nasal pharyngeal aspirates in acute viral respiratory infections by RT-PCR and electrospray ionization mass spectrometry Cluster of oseltamivir-resistant 2009 pandemic infl uenza A (H1N1) virus infections on a hospital ward among immunocompromised patients -North Carolina Performance of laboratory diagnostics for the detection of infl uenza A(H1N1)v virus as correlated with the time after symptom onset and viral load Outbreak of human metapneumovirus infection in psychiatric inpatients: implications for directly observed use of alcohol hand rub in prevention of nosocomial outbreaks Evaluation and verifi cation of the nanosphere Verigene RV+ assay for detection of infl uenza A/B and H1/H3 subtyping Infections caused by Chlamydophila pneumoniae Changing Pertussis epidemiology: everything old is new again Pilot evaluation of RT-PCR/ electrospray ionization mass spectrometry (PLEX-ID/Flu assay) on infl uenza-positive specimens Performance of a rapid assay (Binax NOW) for detection of respiratory syncytial virus at a children's hospital over a 3-year period The atypical pneumonias: clinical diagnosis and importance Comparison of three multiplex PCR assays for the detection of respiratory viral infections: evaluation of xTAG respiratory virus panel fast assay, RespiFinder 19 assay and RespiFinder SMART 22 assay Comparison of fl ocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients Comparison of combined nose-throat swabs with nasopharyngeal aspirates for detection of pandemic infl uenza A/H1N1 2009 virus by realtime reverse transcriptase PCR Rapid and highly sensitive qualitative real-time assay for detection of respiratory syncytial virus A and B using NASBA and molecular beacon technology A large outbreak of Legionnaires' disease at a fl ower show, the Netherlands Infl uenza genome analysis using pyrosequencing method: current applications for a moving target Detection of molecular markers of antiviral resistance in infl uenza A (H5N1) viruses using a pyrosequencing method Detection of molecular markers of drug resistance in 2009 pandemic infl uenza A (H1N1) viruses by pyrosequencing RT-PCR/electrospray ionization mass spectrometry approach in detection and characterization of infl uenza viruses Comparison of Xpert Flu rapid nucleic acid testing with rapid antigen testing for the diagnosis of infl uenza A and B Evaluation and implementation of FilmArray version 1.7 for the improved detection of adenovirus respiratory tract infection Use of the Seeplex RV Detection kit for surveillance of respiratory viral outbreaks in Evaluation of the Xpert Flu rapid PCR assay in high-risk emergency department patients A lean laboratory: operational simplicity and cost effectiveness of the Luminex xTAG™ respiratory viral panel Can newly developed, rapid immunochromatographic antigen detection tests be reliably used for the laboratory diagnosis of infl uenza virus infections? Detection of adenoviruses (AdV) in culture-negative environmental samples by PCR during an AdV-associated respiratory disease outbreak Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Respiratory syncytial virus infection in adults Human metapneumovirus infections in young and elderly adults Viral pneumonia in older adults Legionella and Legionnaires' disease: 25 years of investigation Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis Diagnostic performance of two highly multiplexed respiratory virus assays in a pediatric cohort Nucleic acid amplifi cation tests for detection of respiratory viruses Usefulness of two new methods for diagnosing metapneumovirus infections in children Comparison of the luminex respiratory virus panel fast assay with in-house real-time PCR for respiratory viral infection diagnosis Comparison of a commercial qualitative real-time RT-PCR kit with direct immunofl uorescence assay (DFA) and cell culture for detection of infl uenza A and B in children Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children Sensitivity of a marketed immunochromatographic assay specifi cally targeting the pandemic infl uenza A/H1N1 2009 virus Clinical evaluation of NucliSENS magnetic extraction and NucliSENS analyte-specifi c reagents for real-time detection of human metapneumovirus in pediatric respiratory specimens Quality assurance in clinical virology Likelihood that an unsubtypeable infl uenza A result in the Luminex xTAG Respiratory Virus Panel is indicative of novel A/H1N1 (swine-like) infl uenza Evaluation of multiple test methods for the detection of the novel 2009 infl uenza A (H1N1) during the New York City outbreak Single and multiple respiratory virus infections and severity of respiratory disease: a systematic review Adenovirus: from foe to friend Excessive antibiotic use for acute respiratory infections in the United States Update on rhinovirus and coronavirus infections Comprehensive assessment of 2009 pandemic infl uenza A (H1N1) virus drug susceptibility in vitro Quantitative shedding patterns of respiratory syncytial virus in infants Respiratory syncytial virus and parainfl uenza virus Respiratory virus detection with FilmArray respiratory panel compared to conventional methods in immunocompromised patients A case-control study evaluating RT-PCR/ESI-MS technology compared to direct fl uorescent antibody and xTAG RVP PCR Evaluation of amplifi cation targets for the specifi c detection of Bordetella pertussis using real-time polymerase chain reaction Comparison of two broadly multiplexed PCR systems for viral detection in clinical respiratory tract specimens from immunocompromised children Detection of infl uenza A and B with the Alere i Infl uenza A&B: a novel isothermal nucleic acid amplifi cation assay. Infl uenza Other Respir Viruses Cost-effective use of rapid diagnostic techniques in the treatment and prevention of viral respiratory infections Diagnostic assays for respiratory syncytial virus Human metapneumovirus Swabbing for respiratory viral infections in older patients: a comparison of rayon and nylon fl ocked swabs Verifi cation of the ProPneumo-1 assay for the simultaneous detection of Mycoplasma pneumoniae and Chlamydophila pneumoniae in clinical respiratory specimens Acute pericarditis caused by human metapneumovirus Evaluation of a new, rapid, simple test for the detection of infl uenza virus The changing face of pediatric respiratory tract infections: how human metapneumovirus and human bocavirus fi t into the overall etiology of respiratory tract infections in young children Polymerase-chain reaction/ electrospray ionization-mass spectrometry for the detection of bacteria and fungi in brochoalveolar lavage fl uids: a prospective observational study Comparison of xTAG Respiratory Virus Panel and Verigene Respiratory Virus Plus for detecting infl uenza virus and respiratory syncytial virus Infectious Diseases Society of America. An unmet medical need: Rapid molecular diagnostics for respiratory infections Evaluation of Curetis Unyvero, a multiplex PCR-based testing system, for rapid detection of bacteria and antibiotic resistance and impact of the assay on management of severe nosocomial pneumonia Frequent detection of respiratory viruses without symptoms: toward defi ning clinically relevant cutoff values Human bocavirus-the fi rst 5 years New molecular virus detection methods and their clinical value in lower respiratory tract infections in children Evaluation of the Xpert Flu A Panel nucleic acid amplifi cation-based point-of-care test for infl uenza A virus detection and pandemic H1 subtyping Performance of the Luminex xTAG Respiratory Viral Panel Fast in a clinical laboratory setting Identifi cation of respiratory virus in infants with congenital heart disease by comparison of different methods Rapid detection and identifi cation of 12 respiratory viruses using a dual priming oligonucleotide systembased multiplex PCR assay Evaluation of the Simplexa Flu A/B and RSV test for the rapid detection of infl uenza viruses Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results xTAG RVP assay: analytical and clinical performance Advances in the diagnosis of respiratory tract infections: role of the Luminex xTAG respiratory viral panel The cost of communitymanaged viral respiratory illnesses in a cohort of healthy preschool-aged children Developments in immunologic assays for respiratory viruses Comparison of the Simplexa Flu A/B & RSV PCR with cytospin-immunofl uorescence and laboratorydeveloped TaqMan PCR in predominately adult hospitalized patients Self-collected midturbinate swabs for the detection of respiratory viruses in adults with acute respiratory illnesses Pertussis diagnosis in the 21st century: progress and pitfalls, part 1 Determination of the relative economic impact of different molecular-based laboratory algorithms for respiratory viral pathogen detection, including Pandemic (H1N1), using a secure web based platform To test or to treat? An analysis of infl uenza testing and antiviral treatment strategies using economic computer modeling Identifi cation of adenovirus, infl uenza virus, parainfl uenza virus, and respiratory syncytial virus by two kinds of multiplex polymerase chain reaction (PCR) and a shell vial culture in pediatric patients with viral pneumonia Viral clearance and infl ammatory response patterns in adults hospitalized for pandemic 2009 infl uenza A(H1N1) virus pneumonia Evaluation of the one-step multiplex real-time reverse transcription-PCR ProFlu-1 assay for detection of infl uenza A and infl uenza B viruses and respiratory syncytial viruses in children Role of cell culture for virus detection in the age of technology Description of an adenovirus A31 outbreak in a paediatric haematology unit Incubation periods of acute respiratory viral infections: a systematic review Simultaneous detection and high-throughput identifi cation of a panel of RNA viruses causing respiratory tract infections Rapid diagnosis of infl uenza: an evaluation of two commercially available RT-PCR assays Comparison of viral isolation and multiplex real-time reverse transcription-PCR for confi rmation of respiratory syncytial virus and infl uenza virus detection by antigen immunoassays Identifi cation of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling Respiratory viruses in adults with community-acquired pneumonia Comparison of the FilmArray Respiratory Panel and Prodesse real-time PCR assays for detection of respiratory pathogens Detection of Mycoplasma pneumoniae by real-time nucleic acid sequence-based amplifi cation Development of conventional and real-time nucleic acid sequence-based amplifi cation assays for detection of Chlamydophila pneumoniae in respiratory specimens Development of real-time multiplex nucleic acid sequence-based amplifi cation for detection of Mycoplasma pneumoniae , Chlamydophila pneumoniae , and Legionella spp. in respiratory specimens Evaluation of different nucleic acid amplifi cation techniques for the detection of M. pneumoniae , C. pneumoniae and Legionella spp. in respiratory specimens from patients with community-acquired pneumonia Evaluation of the NucliSens miniMAG RNA extraction and real-time NASBA applications for the detection of Mycoplasma pneumoniae and Chlamydophila pneumoniae in throat swabs Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections Acute respiratory infection due to Mycoplasma pneumoniae : current status of diagnostic methods Performance of different mono-and multiplex nucleic acid amplifi cation tests on a multipathogen external quality assessment panel Antimicrobial stewardship programs in health care systems Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fl uid microbead-based assay Cost analysis of multiplex PCR testing for diagnosing respiratory virus infections Evaluation of Qiagen Resplex II for the detection of pandemic infl uenza A (H1N1) 2009 and infl uenza A (H3N2) virus Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clinical evaluation of NucliSENS magnetic extraction and NucliSENS analyte specifi c reagents for the real-time detection of respiratory syncytial virus (RSV) in paediatric respiratory specimens Multi-center evaluation of the adenovirus R-gene US assay for the detection of adenovirus in respiratory samples Performance of a rapid molecular multiplex assay for the detection of infl uenza and picornaviruses Q fever pneumonia Detection of Mycoplasma pneumoniae in adult community-acquired pneumonia by PCR and serology Developments in tissue culture detection of respiratory viruses Characterization of 2009 pandemic infl uenza A (H1N1) virus specimens with a positive hemagglutinin 1 signal in the Luminex xTAG respiratory viral panel assay Enhanced clinical utility of the NucliSens EasyQ RSV A + B assay for rapid detection of respiratory syncytial virus in clinical samples Evidence of person-toperson transmission of oseltamivir-resistant pandemic infl uenza A(H1N1) 2009 virus in a hematology unit Pandemic infl uenza (H1N1) 2009 pneumonia: CURB-65 score for predicting severity and nasopharyngeal sampling for diagnosis are unreliable Nucleic acid amplifi cation tests for the diagnosis of pneumonia Diagnosis of Legionella infection Evaluation of the pan infl uenza detection kit utilizing the PLEX-ID and infl uenza samples from the 2011 respiratory season The clinical utility of a near patient rapid microarray based diagnostic tests for infl uenza and respiratory syncytial virus infections in a pediatric setting Neuraminidase inhibitor resistance in infl uenza viruses and laboratory testing methods Evaluation of Alere i infl uenza A&B for rapid detection of infl uenza viruses A and B Evaluation of the Cepheid Xpert Flu Assay for rapid identifi cation and differentiation of infl uenza A, infl uenza A 2009 H1N1, and infl uenza B viruses Flocked nasal swab versus nasopharyngeal aspirate for detection of respiratory tract viruses in immunocompromised adults: a matched comparative study A comparison of nested polymerase chain reaction and immunofl uorescence for the diagnosis of respiratory infections in children with bronchiolitis, and the implications for a cohorting strategy Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplifi cation tests for diagnosis of respiratory virus infections Comparison of a singleplex real-time RT-PCR assay and multiplex respiratory viral panel assay for detection of infl uenza "A" in respiratory specimens Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections Genomics and metagenomics in medical microbiology The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals Rhinovirus chemotherapy Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis Rapid detection and identifi cation of human adenovirus species by adenoplex, a multiplex PCR-enzyme hybridization assay Comparison of the Idaho Technology FilmArray system to real-time PCR for detection of respiratory pathogens in children Comparison of the GenMark diagnostics esensor respiratory virus panel to real-time PCR for the detection of respiratory viruses in children FilmArray Respiratory Panel performance of respiratory samples from neonatal care units The underrecognized burden of infl uenza in young children Retrospective and prospective verifi cation of the Cepheid Xpert infl uenza virus assay Comparison of the BioFire FilmArray RP, GenMark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP Fast multiplex assays for the detection of respiratory viruses an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls Upper airway viral infections Comparison of two multiplex methods for detection of respiratory viruses: FilmArray RP and xTAG RVP Comparison of the illumi gene mycoplasma DNA amplifi cation assay and culture for detection of Mycoplasma pneumonia e Timely diagnosis of respiratory tract infections: evaluation of the performance of the Respifi nder assay compared to the xTAG respiratory viral panel assay Respifi nder: a new multiparameter test to differentially identify fi fteen respiratory viruses Emerging oseltamivir resistance in seasonal and pandemic infl uenza A/H1N1 Comparison of FilmArray Respiratory Panel and laboratory-developed real-time reverse transcription-polymerase chain reaction assays for respiratory virus detection Rapid diagnostics and appropriate antibiotic use Epidemiologic and laboratory features of a large outbreak of Pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis -Ohio Impact of a rapid respiratory test panel on patient outcomes Comparison of the Seeplex reverse transcription PCR assay with the R-mix viral culture and immunofl uorescence techniques for detection of eight respiratory viruses Evaluation of the BioFire FilmArray respiratory panel and the GenMark eSensor respiratory viral panel on lower respiratory tract specimens Viral pneumonia Evaluation of the Xpert Flu test and comparison with in-house real-time RT-PCR assays for detection of infl uenza virus from Improved sensitivity of the novel Xpert Flu test for detection of infl uenza B virus Use of rapid infl uenza diagnostic tests under fi eld conditions as a screening tool during an outbreak of the 2009 novel infl uenza virus: practical considerations Validation of the Cepheid Xpert Flu A real time RT-PCR detection panel for emergency use authorization Test characteristics of commercial infl uenza assays for detecting pandemic infl uenza A (H1N1) in children Human bocavirus lessons learned to date pathogens Detection of pneumonia associated pathogens using a prototype multiplexed pneumonia test in hospitalized patients with severe pneumonia Evaluation of three infl uenza A and B real-time reverse transcription-PCR assays and a new 2009 H1N1 assay for detection of infl uenza viruses Evaluation of xTAG Respiratory Viral Panel FAST and xTAG Human Parainfl uenza Virus Analyte-Specifi c Reagents for detection of human parainfl uenza viruses in respiratory specimens Infl uenza and respiratory syncytial virus detection in clinical specimens without nucleic acid extraction using FOCUS direct disc assay is substantially equivalent to the traditional methods and the FOCUS nucleic acid extraction-dependent RT-PCR assay Comparison of the Simplexa Flu A/B and RSV kit (nucleic acid extraction-dependent assay) and the Prodesse ProFlu + assay for detecting infl uenza and respiratory syncytial viruses Why diagnose infl uenza in hospitalized pediatric patients? Detection, identifi cation and distribution of fungi in bronchoalveolar lavage specimens by use of multilocus PCR coupled with electrospray ionization/mass spectrometry Semi-quantitative analysis of infl uenza samples using the Luminex xTAG(®) respiratory viral panel kit Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation Diagnosis of Streptococcus pneumoniae infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection Evaluation of Seeplex RV detection kit for detecting rhinovirus, human metapneumovirus Performance of the Simplexa Flu A/B & RSV Direct kit on respiratory samples collected in saline solution Simultaneous multiple assay (Luminex xTAG respiratory viral panel FAST assay) effi cacy in human respiratory virus detection Evaluation of the broadrange PCR-electrospray ionization mass spectrometry (PCR/ ESI-MS) system and virus microarrays for virus detection Clinical accuracy of a Plex-ID Flu device for simultaneous detection and identifi cation of infl uenza viruses A and B Evaluation of real-time PCR for detection and discrimination between Bordetella pertussis , Bordetella parapertussis , and Bordetella holmesii for clinical diagnosis RSV outbreak in a paediatric intensive care unit Sensitive commercial NASBA assay for the detection of respiratory syncytial virus in clinical specimen Concurrent outbreaks of rhinovirus and respiratory syncytial virus in an intensive care nursery: epidemiology and associated risk Comparison of the FilmArray RP, Verigene RV+, and Prodesse ProFLU+/FAST+ multiplex platforms for detection of infl uenza viruses in clinical samples from the 2011-2012 infl uenza season in Belgium Serological diagnosis of Chlamydia pneumoniae infection: limitations and perspectives Mycoplasma pneumoniae and its role as a human pathogen Comparison of respiratory virus detection rates for infants and toddlers by use of fl ocked swabs, saline aspirates, and saline aspirates mixed in universal transport medium for room temperature storage and shipping Simultaneous detection of respiratory viruses in children with acute respiratory infection using two different multiplex reverse transcription-PCR assays Harmonization of Bordetella pertussis real-time PCR diagnostics in the United States in 2012 Enhanced viral etiological diagnosis of respiratory system infection outbreaks by use of a multitarget nucleic acid amplifi cation assay Cost-effectiveness of rapid diagnosis of viral respiratory tract infections in pediatric patients Comparison of the Simplexa Flu A/B & RSV Direct assay and laboratory-developed real-time PCR assays for detection of respiratory viruses Implementation of FilmArray Respiratory Viral Panel in a core laboratory improves testing turnaround time and patient care Preferential lower respiratory tract infection in swine-origin 2009 A(H1N1) infl uenza Detection of 12 respiratory viruses with two-set multiplex reverse transcriptase-PCR assay using a dual priming oligonucleotide system Molecular epidemiology of two consecutive outbreaks of parainfl uenza 3 in a bone marrow transplant unit Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection Clinical and economical impact of multiplex respiratory virus assays